Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Optic Neuritis × ravulizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 6 Neuromyelitis Optica 2 Recurrence 1 Optic Neuritis 1 Myelitis, Transverse 1 Hemoglobinuria, Paroxysmal 1 Demyelinating Diseases 1 Atypical Hemolytic Uremic Syndrome 1 Adrenal Insufficiency 1

Interventions

eculizumab 3 ublituximab 1 ravulizumab 1 LFB-R603 1 Interferon beta-1a 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04201262 2025-10-14

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

58 enrolled 19 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡